Talkin’ Shop: Industry and Supply Chain Trends for Fuel Systems in 2021

 

Cause and effect is a phrase that certainly applies to the power sports market as it relates to the COVID-19 pandemic. The virus that ground the world to a halt created an explosion of interest in ATVs, UTVs, motorcycles and boats, with sales-generating through the roof.

Mike Coyle, Executive Vice President and President of Fuel Systems Business Unit at Walbro, LLC, explained how this explosive growth in one segment of Walbro’s business required a fundamental shift in how the fuel systems group operates and what to expect from the industry in 2021.

“Last spring, when COVID started to take hold, we had plant shutdowns and so forth, and we got way behind with our customers,” Coyle said. “And then, when the first wave passed and we were allowed to get back into production, of course, all of our customers wanted everything that they had ordered pre-COVID. They wanted it all, like yesterday. So, there was a big effort to try and get caught up with past orders.”

The ongoing challenge for Walbro and its dealers is how to keep up with the growing demand for power sports products, a market that shows no signs of diminishing.

The increase in demand for these power sports products is not limited to the United States; this is a global phenomenon. And Coyle said that Walbro relies on their engine management and fuel systems plants in Thailand to assist with those global demands. These plants are smaller than their Michigan plant but serve an essential function for creating fuel tanks for customers in that area of the world.

“We have a pretty good customer base there, and that is a world-class operation,” Coyle said. “When we measure quality, one of the things we look at is our external defect rate, how many bad parts are returned to us from customers, and we measure that in parts per million. For all of last year the Thailand plants, their quality rate in parts per million was 10. That’s world-class in any industry.”

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More